Dynamics of circulating hypoxia-mediated miRNAs and tumor response in patients with high-grade glioma treated with bevacizumab

Journal of Neurosurgery

Volumn 125, Issue 4, 2016, Pages 1008-1015

  Siegal, Tali ^a,b   Charbit, Hanna ^b   Paldor, Iddo ^c   Zelikovitch, Bracha ^b   Canello, Tamar ^b   Benis, Arriel ^b   Wong, Michael L ^d   Morokoff, Andrew P ^d   Kaye, Andrew H ^d   Lavon, Iris ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b Agnes Ginges Center for Human Neurogenetics   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antiangiogenic therapy; Bevacizumab; Circulating biomarkers; Glioblastoma; High grade glioma; MicroRNA; Oncology; Temozolomide

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; LOMUSTINE; MICRORNA 10B; MICRORNA 21; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE; ANGIOGENESIS INHIBITOR; CIRCULATING MICRORNA;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; HYPOXIA; LONGITUDINAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR VOLUME; BLOOD; BRAIN TUMOR; CANCER GRADING; COMPARATIVE STUDY; GLIOMA; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; BRAIN NEOPLASMS; CIRCULATING MICRORNA; FEMALE; GLIOMA; HUMANS; HYPOXIA; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSPECTIVE STUDIES;

EID: 84990229329     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2015.8.JNS15437     Document Type: Article

References (39)

1. Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, Cloughesy T, et al: Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 88:339-347, 2008
2. Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, et al: Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 117:3140-3146, 2011
3. Baraniskin A, Kuhnhenn J, Schlegel U, Maghnouj A, Zöllner H, Schmiegel W, et al: Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro Oncol 14:29-33, 2012
4. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95, 2007
5. Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603, 2008
6. Chen G, Wang J, Cui Q: Could circulating miRNAs contribute to cancer therapy? Trends Mol Med 19:71-73, 2013
7. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709-722, 2014
8. Ellingson BM, Wen PY, van den Bent MJ, Cloughesy TF: Pros and cons of current brain tumor imaging. Neuro Oncol 16 (Suppl 7):vii2-vii11, 2014
9. Holdhoff M, Yovino SG, Boadu O, Grossman SA: Bloodbased biomarkers for malignant gliomas. J Neurooncol 113:345-352, 2013
10. Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG: Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 32:1978-1985, 2011
11. Ilhan-Mutlu A, Wagner L, Wöhrer A, Jungwirth S, Marosi C, Fischer P, et al: Blood alterations preceding clinical manifestation of glioblastoma. Cancer Invest 30:625-629, 2012
12. Joerger M, Baty F, Früh M, Droege C, Stahel RA, Betticher DC, et al: Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung Cancer 85:306-313, 2014
13. Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, et al: Toward the blood-borne miRNome of human diseases. Nat Methods 8:841-843, 2011
14. Keller A, Leidinger P, Lange J, Borries A, Schroers H, Scheffler M, et al: Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS One 4:e7440, 2009
15. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, et al: Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 108:3749-3754, 2011
16. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745, 2009
17. Kros JM, Mustafa DM, Dekker LJ, Sillevis Smitt PA, Luider TM, Zheng PP: Circulating glioma biomarkers. Neuro Oncol 17:343-360, 2015
18. Lavon I, Refael M, Zelikovitch B, Shalom E, Siegal T: Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro Oncol 12:173-180, 2010
19. Lavon I, Zrihan D, Granit A, Einstein O, Fainstein N, Cohen MA, et al: Gliomas display a microRNA expression profile reminiscent of neural precursor cells. Neuro Oncol 12:422-433, 2010
20. Leidinger P, Keller A, Borries A, Reichrath J, Rass K, Jager SU, et al: High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer 10:262, 2010
21. Liang Y, Ridzon D, Wong L, Chen C: Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 8:166, 2007
22. Lu M, Shi B, Wang J, Cao Q, Cui Q: TAM: a method for enrichment and depletion analysis of a microRNA category in a list of microRNAs. BMC Bioinformatics 11:419, 2010
23. Mestdagh P, Hartmann N, Baeriswyl L, Andreasen D, Bernard N, Chen C, et al: Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nat Methods 11:809-815, 2014
24. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231, 2009
25. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66:1258-1260, 2006
26. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, et al: Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 5:492-497, 2012
27. Redis RS, Calin S, Yang Y, You MJ, Calin GA: Cell-to-cell miRNA transfer: from body homeostasis to therapy. Pharmacol Ther 136:169-174, 2012
28. Roth P, Keller A, Hoheisel JD, Codo P, Bauer AS, Backes C, et al: Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients. Eur J Cancer 51:382-390, 2015
29. Roth P, Wischhusen J, Happold C, Chandran PA, Hofer S, Eisele G, et al: A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem 118:449-457, 2011
30. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, et al: Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306-314, 2000
31. Shen G, Li X, Jia YF, Piazza GA, Xi Y: Hypoxia-regulated microRNAs in human cancer. Acta Pharmacol Sin 34:336-341, 2013
32. Teplyuk NM, Mollenhauer B, Gabriely G, Giese A, Kim E, Smolsky M, et al: MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol 14:689-700, 2012
33. Thompson EM, Frenkel EP, Neuwelt EA: The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 76:87-93, 2011
34. Wagenseller AG, Shada A, D'Auria KM, Murphy C, Sun D, Molhoek KR, et al: MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab. J Transl Med 11:218, 2013
35. Wang Q, Li P, Li A, Jiang W, Wang H, Wang J, et al: Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J Exp Clin Cancer Res 31:97, 2012
36. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963-1972, 2010
37. Witwer KW: Circulating microRNA biomarker studies: pitfalls and potential solutions. Clin Chem 61:56-63, 2015
38. Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F, et al: Identification of seven serum microRNAs from a genomewide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer 132:116-127, 2013
39. Zhi F, Shao N, Wang R, Deng D, Xue L, Wang Q, et al: Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma. Neuro Oncol 17:383-391, 2015